# Ph2 NK Cell Enriched DCIs w/wo RLR9 Agonist, DUK-CPG-001 From Donors Following Allogeneic SCT

> **NCT02452697** · PHASE2 · UNKNOWN · sponsor: **Cristina Gasparetto** · enrollment: 36 (actual)

## Conditions studied

- Myeloid Malignancies
- Lymphoid Malignancies

## Interventions

- **BIOLOGICAL:** NK Cell enriched-DLI only
- **BIOLOGICAL:** NK-DLI + DUK-CPG-001

## Key facts

- **NCT ID:** NCT02452697
- **Lead sponsor:** Cristina Gasparetto
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2016-06-08
- **Primary completion:** 2022-07-23
- **Final completion:** 2024-10
- **Target enrollment:** 36 (ACTUAL)
- **Last updated:** 2024-02-20

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02452697

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02452697, "Ph2 NK Cell Enriched DCIs w/wo RLR9 Agonist, DUK-CPG-001 From Donors Following Allogeneic SCT". Retrieved via AI Analytics 2026-06-10 from https://api.ai-analytics.org/clinical/NCT02452697. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*